Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

L. E. M. Oosten*, M. E. D. Chamuleau, F. W. Thielen, L. C. de Wreede, C. Siemes, J. K. Doorduijn, O. S. Smeekes, M. J. Kersten, L. Hardi, J. W. Baars, A. M. P. Demandt, W. B. C. Stevens, M. Nijland, G. W. van Imhoff, R. Brouwer, C. A. Uyl-de Groot, P. M. Kluin, D. de Jong, H. Veelken

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
291 Downloads (Pure)


Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Munster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19 patients, HOVON 29 patients, and CODOX-M/IVAC 21 patients (median age 39 years, range 1474; mean duration of follow-up 47 months). There was no significant difference between age, sex ratio, disease stage, or percentage HIV-positive patients between the treatment groups. Five-year progression-free survival (69%, p = 0.966) and 5-year overall survival (69%, p = 0.981) were comparable for all treatment groups. Treatment-related toxicity was also comparable with only hepatotoxicity seen more frequently in the CODOX/M-IVAC group (p = 0.004). Costs were determined by the number of rituximab gifts and the number of inpatients days. Overall, CODOX-M/IVAC had the most beneficial profile with regards to costs, treatment duration, and percentage of patients completing planned treatment. We conclude that the four treatment protocols for Burkitt lymphoma yield nearly identical results with regards to efficacy and safety but differ in treatment duration and costs. These differences may help guide future choice of treatment.

Original languageEnglish
Pages (from-to)255-266
Number of pages12
JournalAnnals of Hematology
Issue number2
Publication statusPublished - Feb-2018


  • Burkitt lymphoma
  • Drugtherapy
  • Survival
  • Cost nalysis

Cite this